[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.168.204. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 376
Citations 0
Correspondence
February 2013

What Is the True Clinicopathologic Spectrum of Neuromyelitis Optica?—Reply

Author Affiliations

Author Affiliations: Department of Neurology, University of Texas Southwestern Medical Center, Dallas (Dr Greenberg); Department of Neurology, Mayo Clinic, Scottsdale, Arizona (Dr Wingerchuk); and Department of Neurology, Johns Hopkins Hospital, Baltimore, Maryland (Ms Mealy and Dr Levy).

JAMA Neurol. 2013;70(2):272-273. doi:10.1001/jamaneurol.2013.1286

In reply

We appreciate the comments of Drs Govindarajan and Salgado relative to our article about the clinicopathologic spectrum of neuromyelitis optica (NMO)/NMO spectrum disorder. They point out 2 other potential clinical manifestations of NMO and question the conclusions relative to natalizumab and interferon therapy.

The cases presented do indeed represent potential presentations for NMO. The first case describes a patient who presented with clinical and radiographic evidence of myeloradiculitis and whose test results were subsequently found to be positive for the anti–aquaporin 4 (AQP4) antibody. The second case involves a patient with generalized pruritus preceding myelitis and whose test results were positive for anti-AQP4 antibody. While our case series did not specifically record these patient types, it is worth noting 2 observations.

First Page Preview View Large
First page PDF preview
First page PDF preview
×